| P50 | author | Jean-Jacques Lefrère | Q3166331 |
| | Syria Laperche | Q28595169 |
| | Bruno Pozzetto | Q64763423 |
| | Fabrice Cognasse | Q89934483 |
| | Patricia Chavarin | Q120563441 |
| | Jean-Daniel Tissot | Q37837135 |
| | Miquel Lozano | Q43853754 |
| P2093 | author name string | Olivier Garraud | |
| | Neil Blumberg | |
| | Pascal Morel | |
| | Jean-Claude Osselaer | |
| P2860 | cites work | Diagnostic methods for platelet bacteria screening: current status and developments | Q27021920 |
| | The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates | Q27027674 |
| | Pathogen inactivation technologies for cellular blood components: an update | Q28655769 |
| | Blood transfusion safety: a new philosophy | Q30423927 |
| | Dose of prophylactic platelet transfusions and prevention of hemorrhage | Q30496886 |
| | The blood donors' haemovigilance in France | Q33162658 |
| | Estimation and predictive use of the corrected count increment--a proposed clinical guideline | Q33365212 |
| | Introduction of platelet additive solution in platelet concentrates: towards a decrease of blood transfusion reactions | Q33381674 |
| | Platelet transfusion: products, indications, dose, threshold and efficacy | Q33384501 |
| | Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction | Q33389833 |
| | Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system | Q33397396 |
| | Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study | Q33402744 |
| | The observation of bleeding complications in haemato-oncological patients: stringent watching, relevant reporting. | Q33403659 |
| | Platelet transfusion: a clinical practice guideline from the AABB. | Q33418628 |
| | A computerized prediction model of hazardous inflammatory platelet transfusion outcomes | Q33618448 |
| | Contribution of activated platelets to plasma IL-27 levels. | Q33752713 |
| | Microcirculatory effects of the transfusion of leukodepleted or non-leukodepleted red blood cells in patients with sepsis: a pilot study. | Q33754405 |
| | French Haemovigilance Data on Platelet Transfusion | Q33879573 |
| | An approach to prevent the severe adverse events associated with transfusion of FDA-approved blood products. | Q50580384 |
| | Proteomic analysis of platelets treated with gamma irradiation versus a commercial photochemical pathogen reduction technology. | Q51540517 |
| | Transfusion from male-only versus female donors in critically ill recipients of high plasma volume components. | Q51752325 |
| | Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. | Q51851000 |
| | Counting platelets at transfusion threshold levels: impact on the decision to transfuse. A BEST Collaborative - UK NEQAS(H) International Exercise. | Q53098496 |
| | Removal of biologic response modifiers associated with platelet transfusion reactions: strategies worth considering? | Q53418681 |
| | In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage. | Q53563734 |
| | [Who are the recipients of labile blood products? A multicenter nation-wide study--a "donation day." Blood banks, health facilities]. | Q54114828 |
| | Pathogen inactivation technology applied to a blood component collected from an asymptomatic carrier of Leishmania infantum: a case report. | Q54304366 |
| | Bacterial contamination in platelet concentrates | Q58802953 |
| | Platelet Transfusion Therapy | Q61943894 |
| | Donor platelets stored for at least 3 days can elicit activation marker expression by the recipient's blood mononuclear cells: an in vitro study | Q79710832 |
| | Release of potential immunomodulatory factors during platelet storage | Q79889339 |
| | Release of immune modulation factors from platelet concentrates during storage after photochemical pathogen inactivation treatment | Q80769138 |
| | Satisfaction survey in general hospital personnel involved in blood transfusion: implementation of the ISO 9001: 2000 standard | Q81058066 |
| | Platelet components associated with acute transfusion reactions: the role of platelet-derived soluble CD40 ligand | Q82705714 |
| | Evaluation of platelet transfusion clinical trials | Q83319230 |
| | Adverse effects of 'old' versus 'young' blood: also true for platelet concentrates? | Q83891017 |
| | Amotosalen-HCl-UVA pathogen reduction does not alter poststorage metabolism of soluble CD40 ligand, Ox40 ligand and interkeukin-27, the cytokines that generally associate with serious adverse events | Q85837811 |
| | [Control of the bacterial risk of transfusion in France in 2013] | Q86669697 |
| | Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion | Q88053423 |
| | Impact of leucocyte depletion and prion reduction filters on TSE blood borne transmission | Q34364427 |
| | The international experience of bacterial screen testing of platelet components with an automated microbial detection system: a need for consensus testing and reporting guidelines | Q34410505 |
| | Variant CJD. 18 years of research and surveillance | Q34453109 |
| | Concepts of blood transfusion in adults | Q34652259 |
| | Non-leukodepleted red blood cell transfusion in sepsis patients: beyond oxygenation, is there a risk of inflammation? | Q34659126 |
| | The French surveillance network of Creutzfeldt-Jakob disease. Epidemiological data in France and worldwide | Q34669627 |
| | Platelet transfusions: Impact on hemostasis, thrombosis, inflammation and clinical outcomes | Q34708937 |
| | Detection of the GPI-anchorless prion protein fragment PrP226* in human brain. | Q34996457 |
| | The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility | Q35043259 |
| | Transfusion immunomodulation--the case for leukoreduced and (perhaps) washed transfusions | Q36428284 |
| | The impact of policies to restrict the use of plasma containing products and apheresis platelets from female donors to mitigate transfusion related acute lung injury (TRALI) in Brazil | Q36539900 |
| | Lyophilized platelets: fifty years in the making | Q36761369 |
| | Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century | Q36817997 |
| | Transfusion-related immunomodulation (TRIM): an update | Q36931168 |
| | The pro-inflammatory effects of platelet contamination in plasma and mitigation strategies for avoidance | Q36950012 |
| | Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies | Q37026225 |
| | Platelet transfusion - the art and science of compromise | Q37049262 |
| | Quantitative analysis of DNA interstrand cross-links and monoadducts formed in human cells induced by psoralens and UVA irradiation | Q37060565 |
| | CD40 ligand (CD154) involvement in platelet transfusion reactions | Q37429101 |
| | Emerging Pathogens - How Safe is Blood? | Q37630317 |
| | Are polymorphisms of the immunoregulatory factor CD40LG implicated in acute transfusion reactions? | Q37741117 |
| | Platelet Toll-like receptor expression: the link between "danger" ligands and inflammation | Q37762278 |
| | White blood cell inactivation after treatment with riboflavin and ultraviolet light | Q37763276 |
| | Platelets and the immune continuum | Q37857647 |
| | New thoughts on the correct dosing of prophylactic platelet transfusions to prevent bleeding | Q37938487 |
| | Clinical effects of leucoreduction of blood transfusions. | Q37953345 |
| | Trypanosoma cruzi infection in North America and Spain: evidence in support of transfusion transmission | Q37982844 |
| | HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management | Q37990036 |
| | Platelet storage and transfusions: new concerns associated with an old therapy | Q38015853 |
| | ABO incompatible platelets: risks versus benefit | Q38036890 |
| | Emerging pathogens and their implications for the blood supply and transfusion transmitted infections | Q38038210 |
| | A reporting guideline for clinical platelet transfusion studies from the BEST Collaborative | Q38045932 |
| | The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions | Q38073018 |
| | Bench-to-bedside review: Platelets and active immune functions - new clues for immunopathology? | Q38133641 |
| | Age of blood: does older blood yield poorer outcomes? | Q38150632 |
| | Root cause analysis of non-infectious transfusion complications and the lessons learnt | Q38163206 |
| | Automation of blood component preparation from whole blood collections. | Q38180463 |
| | Safety of platelet transfusion: past, present and future. | Q38197714 |
| | Detection of malarial DNA in blood donors--evidence of persistent infection. | Q38198105 |
| | Novel platelet storage conditions: additive solutions, gas, and cold. | Q38241900 |
| | Profiling alterations in platelets induced by Amotosalen/UVA pathogen reduction and gamma irradiation--a LC-ESI-MS/MS-based proteomics approach | Q38495417 |
| | Degenerate polymerase chain reaction strategy with DNA microarray for detection of multiple and various subtypes of virus during blood screening | Q39434473 |
| | Current status of additive solutions for platelets | Q39657480 |
| | Viremic profiles in asymptomatic and symptomatic chikungunya fever: a blood transfusion threat? | Q40267017 |
| | West Nile virus infection in blood donors in the New York City area during the 2010 seasonal epidemic | Q40290912 |
| | Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico | Q40296125 |
| | Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion | Q40393933 |
| | Influence of blood prestorage conditions and white blood cell filtration on the bacterial load of blood deliberately inoculated with Gram-positive and Gram-negative pathogens. | Q41460448 |
| | Reduction of Yersinia enterocolitica load in deliberately inoculated blood: the effects of blood prestorage temperature and WBC filtration. | Q41471569 |
| | Residual risk and retrospective analysis of transfusion-transmitted bacterial infection reported by the French National Hemovigilance Network from 2000 to 2008. | Q41725748 |
| | Biological response modifiers in photochemically pathogen-reduced versus untreated apheresis platelet concentrates | Q41965815 |
| | Microconductometric immunosensor for label-free and sensitive detection of Gram-negative bacteria | Q42238556 |
| | Multiplex screening for blood-borne viral, bacterial, and protozoan parasites using an OpenArray platform | Q42242052 |
| | Voluntary non-remunerated blood donation and reasons for donating: is there room for philosophy? | Q42430777 |
| | The abandoned controversy surrounding universal white blood cell reduction | Q42604107 |
| | Do manual and automated processes with distinct additive solutions affect whole blood-derived platelet components differently? | Q43051741 |
| | Apheresis affects bone and mineral metabolism | Q43239431 |
| | In vitro and in vivo quality of leukoreduced apheresis platelets stored in a new platelet additive solution | Q43557212 |
| | Use of random versus apheresis platelet concentrates | Q44113335 |
| | Reduction of adverse citrate reactions during autologous large‐volume PBPC apheresis by continuous infusion of calcium‐gluconate | Q44655712 |
| | Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation | Q44827919 |
| | Blood donor hemovigilance: impact for donor and recipient safety | Q44841182 |
| | Frozen platelets for rural Australia: the CLIP trial | Q45008810 |
| | Immune-reactive soluble OX40 ligand, soluble CD40 ligand, and interleukin-27 are simultaneously oversecreted in platelet components associated with acute transfusion reactions. | Q45832206 |
| | Development of a quality monitoring program for platelet components: a report of the first four years' experience at Canadian Blood Services | Q45836447 |
| | Electrochemical aptasensor of cellular prion protein based on modified polypyrrole with redox dendrimers. | Q46568722 |
| | Random aggregates in newly produced platelet units are associated with platelet activation and release of the immunomodulatory factors sCD40L and RANTES. | Q46653073 |
| | Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants | Q46902802 |
| | Evaluation of a rapid colorimetric assay for detection of bacterial contamination in apheresis and pooled random-donor platelet units | Q46918266 |
| | Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy. | Q46948508 |
| | Risk assessment of transfusion-associated babesiosis in Tyrol: appraisal by seroepidemiology and polymerase chain reaction | Q47861373 |
| | Challenges and opportunities to prevent transfusion errors: a Qualitative Evaluation for Safer Transfusion (QUEST). | Q50147413 |
| | Removal of biological response modifiers associated with platelet transfusion reactions by columns containing adsorption beads. | Q50481057 |
| | Anti-leucocyte antibodies in platelet apheresis donors with and without prior immunizing events: implications for TRALI prevention. | Q50489643 |
| | Significant bacterial contamination risk reduction with the use of diversion pouch. | Q50502476 |
| | ??? | Q56894666 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | platelet transfusion | Q23925170 |
| P304 | page(s) | 109-122 | |
| P577 | publication date | 2015-11-16 | |
| P1433 | published in | Blood transfusion = Trasfusione del sangue | Q26842792 |
| P1476 | title | Improving platelet transfusion safety: biomedical and technical considerations | |
| P478 | volume | 14 | |